Havn Life Sciences Inc. Announces Appointment of Gary Leong as Chief Science Officer


Ryan Allway

July 7th, 2020

Psychedelics


Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces the appointment of Gary Leong as Chief Science Officer of Havn Life. Mr. Leong has over thirty (30) years of experience in the Pharmaceutical and Natural Health Products (“NHP”) industry.

Mr. Leong was the Chief Scientific Officer at Aphria Inc. in Leamington, ON from its inception in 2014 to 2019. At Aphria, Gary established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs and Research and Development functions. Prior to this, Gary served as the Chief Scientific Officer Jamieson Laboratories in Windsor, ON for fourteen (14) years. He has managed the scientific and quality function for Boehringer Ingelheim, Natural Factors Nutritional Products Ltd. and Nordion. Gary holds a B.Sc. in Chemistry and a M.B.A. in Quality Management. Gary has served on the Board of Directors of several public companies and research societies as well as an advisor to several Canadian government regulatory advisory committees.

Mr. Leong will work with the team at Havn Life to develop formulations for Havn Life’s Retail division which will look to bring NHP products that include novel psychoactive compounds to health food stores across the country. In addition, he will also work with the Havn Lab’s team to develop and plan research studies relating to the potential health benefits of psilocybin and other psychoactive compounds.

Havn Life’s Co-CEO, Susan Chapelle stated, “Mr. Leong has a long track record of developing products and formulations for the NHP industry as well as being involved in research. His experience makes him an incredible asset for the Havn Team, and we look forward to building both the Retail and Labs divisions of Havn with his capabilities.”

On Behalf
Susan Chapelle & Tim Moore
Co-CEOs

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human performance using evidence-informed research. The company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds. Havn Life’s research facility, Havn Labs, is located in the South Campus at The University of British Columbia (UBC).

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading